Latest news with #TXG
Yahoo
23-05-2025
- Business
- Yahoo
1 Small-Cap Stock with Exciting Potential and 2 to Turn Down
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats. The downside that can come from buying these securities is precisely why we started StockStory - to isolate the long-term winners from the losers so you can invest with confidence. Keeping that in mind, here is one small-cap stock that could amplify your portfolio's returns and two that could be down big. Market Cap: $1.05 billion Founded in 2012 by scientists seeking to overcome limitations in traditional biological research methods, 10x Genomics (NASDAQ:TXG) develops instruments, consumables, and software that enable researchers to analyze biological systems at single-cell resolution and spatial context. Why Is TXG Risky? Cash burn makes us question whether it can achieve sustainable long-term growth Negative returns on capital show that some of its growth strategies have backfired, and its decreasing returns suggest its historical profit centers are aging Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions At $8.45 per share, 10x Genomics trades at 1.8x forward price-to-sales. Read our free research report to see why you should think twice about including TXG in your portfolio, it's free. Market Cap: $8.90 billion With a history dating back to 1902 and roots in the McCann-Erickson agency, Interpublic Group (NYSE:IPG) is a marketing and communications holding company that owns agencies specializing in advertising, media buying, public relations, and digital marketing services. Why Should You Dump IPG? Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth Sales are projected to tank by 3.2% over the next 12 months as its demand continues evaporating 9.6 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position Interpublic Group's stock price of $24.06 implies a valuation ratio of 8.9x forward P/E. To fully understand why you should be careful with IPG, check out our full research report (it's free). Market Cap: $910.7 million Transforming how doctors care for seniors by shifting financial incentives from volume to outcomes, agilon health (NYSE:AGL) provides a platform that helps primary care physicians transition to value-based care models for Medicare patients through long-term partnerships and global capitation arrangements. Why Does AGL Stand Out? Annual revenue growth of 40.5% over the past two years was outstanding, reflecting market share gains this cycle Customer trends over the past two years show it's maintaining a steady flow of new contracts that can potentially increase in value over time Earnings growth has trumped its peers over the last three years as its EPS has compounded at 14.5% annually agilon health is trading at $2.25 per share, or 0.1x forward price-to-sales. Is now a good time to buy? See for yourself in our comprehensive research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free.
Yahoo
08-05-2025
- Business
- Yahoo
10x Genomics (NASDAQ:TXG) shareholders have endured a 90% loss from investing in the stock five years ago
Long term investing works well, but it doesn't always work for each individual stock. We don't wish catastrophic capital loss on anyone. Imagine if you held 10x Genomics, Inc. (NASDAQ:TXG) for half a decade as the share price tanked 90%. And we doubt long term believers are the only worried holders, since the stock price has declined 67% over the last twelve months. Furthermore, it's down 43% in about a quarter. That's not much fun for holders. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. 10x Genomics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit. Over five years, 10x Genomics grew its revenue at 18% per year. That's well above most other pre-profit companies. So it's not at all clear to us why the share price sunk 14% throughout that time. You'd have to assume the market is worried that profits won't come soon enough. While there might be an opportunity here, you'd want to take a close look at the balance sheet strength. The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers). It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. So we recommend checking out this free report showing consensus forecasts While the broader market gained around 9.3% in the last year, 10x Genomics shareholders lost 67%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 14% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with 10x Genomics , and understanding them should be part of your investment process. There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
12-02-2025
- Business
- Yahoo
Seeking Clues to 10x Genomics (TXG) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Wall Street analysts expect 10x Genomics (TXG) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158.14 million, down 14% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe. Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights. Given this perspective, it's time to examine the average forecasts of specific 10x Genomics metrics that are routinely monitored and predicted by Wall Street analysts. The collective assessment of analysts points to an estimated 'Revenues- Consumables' of $128.51 million. The estimate suggests a change of -8.4% year over year. Analysts' assessment points toward 'Revenues- Instruments' reaching $19.02 million. The estimate indicates a change of -50.5% from the prior-year quarter. Based on the collective assessment of analysts, 'Revenues- Services' should arrive at $6.52 million. The estimate points to a change of +23.7% from the year-ago all Key Company Metrics for 10x Genomics here>>>Over the past month, 10x Genomics shares have recorded returns of -23.2% versus the Zacks S&P 500 composite's +4.2% change. Based on its Zacks Rank #3 (Hold), TXG will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report 10x Genomics (TXG) : Free Stock Analysis Report To read this article on click here. Zacks Investment Research Sign in to access your portfolio
